catalyst

The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) — primary completion

as of 2026-07-01
Monitor thisAsk about this
at a glance
2017-12 · Actual — This event happened.
Synthesized from structured facts only — each point cited above.

Event

What
The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) — primary completion
Type
Trial Readout
Date
2017-12
Date type
ACTUAL
Phase
Phase 2
This event happened.
relationships
The graph out of here
trial
The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia
trial